Shots: NMPA has approved HLX03 for the treatment of RA, AS and PsO. It is the first China-developed biosimilar, approved both in China and in the EU The approval marks […]readmore
Tags : HLX03
Shots: The P-III HLX03-Ps03 study involves comparing the efficacy, safety and immunogenicity assessing of HLX03 (80mg, qd) with reference adalimumab in 262 Chinese patients in the ratio of (1:1) with […]readmore